Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017

  • ID: 4327553
  • Report
  • 1676 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • Bayer AG
  • Emercell SAS
  • Immune System Key Ltd
  • Merck KGaA
  • Phylogica Ltd
  • MORE
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 18, 98, 105, 1, 5, 171, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 16, 14, 31 and 13 molecules, respectively.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • Bayer AG
  • Emercell SAS
  • Immune System Key Ltd
  • Merck KGaA
  • Phylogica Ltd
  • MORE
Introduction

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Companies, H1 2017 (Contd..3), H1

Number of Products under Development by Companies, H1 2017 (Contd..4), H1

Number of Products under Development by Companies, H1 2017 (Contd..5), H1

Number of Products under Development by Companies, H1 2017 (Contd..6), H1

Number of Products under Development by Companies, H1 2017 (Contd..7), H1

Number of Products under Development by Companies, H1 2017 (Contd..8), H1

Number of Products under Development by Companies, H1 2017 (Contd..9), H1

Number of Products under Development by Companies, H1 2017 (Contd..10), H1

Number of Products under Development by Companies, H1 2017 (Contd..11), H1

Number of Products under Development by Companies, H1 2017 (Contd..12), H1

Number of Products under Development by Companies, H1 2017 (Contd..13), H1

Number of Products under Development by Universities/Institutes, H1

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Companies, H1 2017 (Contd..3), H1

Products under Development by Companies, H1 2017 (Contd..4), H1

Products under Development by Companies, H1 2017 (Contd..5), H1

Products under Development by Companies, H1 2017 (Contd..6), H1

Products under Development by Companies, H1 2017 (Contd..7), H1

Products under Development by Companies, H1 2017 (Contd..8), H1

Products under Development by Companies, H1 2017 (Contd..9), H1

Products under Development by Companies, H1 2017 (Contd..10), H1

Products under Development by Companies, H1 2017 (Contd..11), H1

Products under Development by Companies, H1 2017 (Contd..12), H1

Products under Development by Companies, H1 2017 (Contd..13), H1

Products under Development by Companies, H1 2017 (Contd..14), H1

Products under Development by Companies, H1 2017 (Contd..15), H1

Products under Development by Companies, H1 2017 (Contd..16), H1

Products under Development by Companies, H1 2017 (Contd..17), H1

Products under Development by Companies, H1 2017 (Contd..18), H1

Products under Development by Companies, H1 2017 (Contd..19), H1

Products under Development by Companies, H1 2017 (Contd..20), H1

Products under Development by Companies, H1 2017 (Contd..21), H1

Products under Development by Companies, H1 2017 (Contd..22), H1

Products under Development by Companies, H1 2017 (Contd..23), H1

Products under Development by Companies, H1 2017 (Contd..24), H1

Products under Development by Companies, H1 2017 (Contd..25), H1

Products under Development by Companies, H1 2017 (Contd..26), H1

Products under Development by Companies, H1 2017 (Contd..27), H1

Products under Development by Companies, H1 2017 (Contd..28), H1

Products under Development by Companies, H1 2017 (Contd..29), H1

Products under Development by Universities/Institutes, H1

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1

Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Target, H1 2017 (Contd..2), H1

Number of Products by Stage and Target, H1 2017 (Contd..3), H1

Number of Products by Stage and Target, H1 2017 (Contd..4), H1

Number of Products by Stage and Target, H1 2017 (Contd..5), H1

Number of Products by Stage and Target, H1 2017 (Contd..6), H1

Number of Products by Stage and Target, H1 2017 (Contd..7), H1

Number of Products by Stage and Target, H1 2017 (Contd..8), H1

Number of Products by Stage and Target, H1 2017 (Contd..9), H1

Number of Products by Stage and Target, H1 2017 (Contd..10), H1

Number of Products by Stage and Target, H1 2017 (Contd..11), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics Sarl, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Alexion Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptose Biosciences Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by arGEN-X BV, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Asterias Biotherapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio ASA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioSight Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Blueprint Medicines Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boston Biomedical Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Calithera Biosciences Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cascadian Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cell Medica Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectar Biosciences Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectis SA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellular Biomedicine Group Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celyad SA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CharlestonPharma LLC, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cielo Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ConverGene LLC, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CSPC Pharmaceutical Group Limited, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CTI BioPharma Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Daiichi Sankyo Company Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DC Prime BV, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by eFFECTOR Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Company, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Emercell SAS, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem SL, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EpiZyme Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Erytech Pharma SA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Exelixis Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fate Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by FLX Bio Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Forma Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fortress Biotech Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Forty Seven Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fujifilm Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genoscience Pharma, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gilead Sciences Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Glycostem Therapeutics BV, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Golden Biotechnology Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by H3 Biomedicine Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hybrigenics SA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Igenica Biotherapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by IGF Oncology LLC, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ignyta Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune System Key Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunGene Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunoGen Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immunomedics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Incyte Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Inflection Biosciences Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Innovation Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Interprotein Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Io Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jasco Pharmaceuticals LLC, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jazz Pharmaceuticals Plc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jeil Pharmaceutical Co Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Johnson & Johnson, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by JW Pharmaceutical Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kainos Medicine Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kiadis Pharma NV, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kite Pharma Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Komipharm International Co Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kura Oncology Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kyowa Hakko Kirin Co Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Lead Discovery Center GmbH, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MacroGenics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mateon Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MaxCyte Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by medac GmbH, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MediGene AG, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MedImmune LLC, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Medivir AB, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MEI Pharma Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck & Co Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck KGaA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merus NV, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Miltenyi Biotec GmbH, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by miRagen Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mirati Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Moleculin Biotech Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MolMed SpA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NantKwest Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nerviano Medical Sciences Srl, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Neumedicines Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NewLink Genetics Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Novartis AG, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NuCana BioMed Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Omeros Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoImmune Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onconova Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoTartis Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoTherapy Science Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncternal Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Otsuka Holdings Co Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oxford BioTherapeutics Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OXIS International Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Panacea Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pfizer Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharma Mar SA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmascience Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmedartis GmbH, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Philogen SpA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Phylogica Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Plexxikon Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Polaris Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by PTC Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rafael Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Resverlogix Corp, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rich Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rigel Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sanofi, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sareum Holdings Plc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Seattle Genetics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Selvita SA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Senhwa Biosciences Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Shire Plc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sierra Oncology Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sigma-Tau SpA, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sorrento Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Stemline Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sunesis Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syndax Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syros Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TaiGen Biotechnology Co Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Taiho Pharmaceutical Co Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Takara Bio Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Takeda Pharmaceutical Company Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Teva Pharmaceutical Industries Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tolero Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TRACON Pharmaceuticals Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Trillium Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Trovagene Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by VasGene Therapeutics Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Vichem Chemie Research Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Viralytics Ltd, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xencor Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xenetic Biosciences Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ZIOPHARM Oncology Inc, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..1), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..2), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..3), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..4), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..5), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..6), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..7), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..8), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..9), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..10), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2017 (Contd..11), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H1 2017 (Contd..1), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H1 2017 (Contd..2), H1

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H1 2017 (Contd..3), H1

List of Figures

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Top 10 Routes of Administration, H1

Number of Products by Stage and Top 10 Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4SC AG
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AB Science SA
  • AbbVie Inc
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics Sarl
  • Advenchen Laboratories LLC
  • Aeglea BioTherapeutics Inc
  • Affichem SA
  • Agios Pharmaceuticals Inc
  • Aileron Therapeutics Inc
  • AIMM Therapeutics BV
  • Alexion Pharmaceuticals Inc
  • Altor BioScience Corp
  • Amgen Inc
  • Antigen Express Inc
  • Antisense Therapeutics Ltd
  • APIM Therapeutics AS
  • Aptevo Therapeutics Inc
  • Aptose Biosciences Inc
  • arGEN-X BV
  • Ariad Pharmaceuticals Inc
  • Arno Therapeutics Inc
  • Arog Pharmaceuticals Inc
  • Array BioPharma Inc
  • Aslan Pharmaceuticals Pte Ltd
  • Astellas Pharma Inc
  • Asterias Biotherapeutics Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Athenex Inc
  • Aurigene Discovery Technologies Ltd
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • BCI Pharma
  • Bellicum Pharmaceuticals Inc
  • BerGenBio ASA
  • Bio-Cancer Treatment International Ltd
  • Bio-Path Holdings Inc
  • BioLineRx Ltd
  • BioSight Ltd
  • Blueprint Medicines Corp
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Company
  • Calithera Biosciences Inc
  • Cancer Therapeutics CRC Pty Ltd
  • Cantargia AB
  • Cantex Pharmaceuticals Inc
  • Cascadian Therapeutics Inc
  • Celgene Corp
  • Cell Medica Ltd
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Cellectis SA
  • Cellerant Therapeutics Inc
  • Cellular Biomedicine Group Inc
  • Celyad SA
  • CharlestonPharma LLC
  • Cielo Therapeutics Inc
  • ConverGene LLC
  • Critical Outcome Technologies Inc
  • CSPC Pharmaceutical Group Limited
  • CTI BioPharma Corp
  • Cyclacel Pharmaceuticals Inc
  • Daiichi Sankyo Company Ltd
  • DC Prime BV
  • Deciphera Pharmaceuticals LLC
  • eFFECTOR Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Emercell SAS
  • EntreChem SL
  • EpiZyme Inc
  • Erytech Pharma SA
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • FLX Bio Inc
  • Forma Therapeutics Inc
  • Formula Pharmaceuticals Inc
  • Fortress Biotech Inc
  • Forty Seven Inc
  • Fujifilm Corp
  • Gamida Cell Ltd
  • Genentech Inc
  • Genoscience Pharma
  • Genosco Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GlycoMimetics Inc
  • Glycostem Therapeutics BV
  • Golden Biotechnology Corp
  • H3 Biomedicine Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Hybrigenics SA
  • Igenica Biotherapeutics Inc
  • IGF Oncology LLC
  • Ignyta Inc
  • Immune Pharmaceuticals Inc
  • Immune System Key Ltd
  • ImmunGene Inc
  • ImmunoGen Inc
  • Immunomedics Inc
  • Incyte Corp
  • Inflection Biosciences Ltd
  • Innovation Pharmaceuticals Inc
  • Interprotein Corp
  • Io Therapeutics Inc
  • Jasco Pharmaceuticals LLC
  • Jazz Pharmaceuticals Plc
  • Jeil Pharmaceutical Co Ltd
  • Johnson & Johnson
  • JW Pharmaceutical Corp
  • Kainos Medicine Inc
  • Karyopharm Therapeutics Inc
  • Kiadis Pharma NV
  • Kite Pharma Inc
  • Komipharm International Co Ltd
  • Kura Oncology Inc
  • Kyowa Hakko Kirin Co Ltd
  • Lead Discovery Center GmbH
  • Les Laboratoires Servier SAS
  • MacroGenics Inc
  • Mateon Therapeutics Inc
  • MaxCyte Inc
  • medac GmbH
  • MediGene AG
  • MedImmune LLC
  • Medivir AB
  • MEI Pharma Inc
  • Merck & Co Inc
  • Merck KGaA
  • Merus NV
  • Millennium Pharmaceuticals Inc
  • Miltenyi Biotec GmbH
  • miRagen Therapeutics Inc
  • Mirati Therapeutics Inc
  • Moleculin Biotech Inc
  • MolMed SpA
  • NantKwest Inc
  • Nerviano Medical Sciences Srl
  • Neumedicines Inc
  • NewLink Genetics Corp
  • Novartis AG
  • NuCana BioMed Ltd
  • Omeros Corp
  • OncoImmune Inc
  • Onconova Therapeutics Inc
  • OncoTartis Inc
  • OncoTherapy Science Inc
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Otsuka Holdings Co Ltd
  • Oxford BioTherapeutics Ltd
  • OXIS International Inc
  • Panacea Pharmaceuticals Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Pharmascience Inc
  • Pharmedartis GmbH
  • Philogen SpA
  • Phylogica Ltd
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • PTC Therapeutics Inc
  • Rafael Pharmaceuticals Inc
  • Resverlogix Corp
  • Rich Pharmaceuticals Inc
  • Rigel Pharmaceuticals Inc
  • Sanofi
  • Sareum Holdings Plc
  • Seattle Genetics Inc
  • Selvita SA
  • Senhwa Biosciences Inc
  • Shire Plc
  • Sierra Oncology Inc
  • Sigma-Tau SpA
  • Sorrento Therapeutics Inc
  • Spectrum Pharmaceuticals Inc
  • Stemline Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Sunesis Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • SYNIMMUNE GmbH
  • Syros Pharmaceuticals Inc
  • TaiGen Biotechnology Co Ltd
  • Taiho Pharmaceutical Co Ltd
  • Takara Bio Inc
  • Takeda Pharmaceutical Company Ltd
  • Teva Pharmaceutical Industries Ltd
  • Tolero Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
  • Trillium Therapeutics Inc
  • Trovagene Inc
  • VasGene Therapeutics Inc
  • Vichem Chemie Research Ltd
  • Viralytics Ltd
  • Xencor Inc
  • Xenetic Biosciences Inc
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll